Anivive Lifesciences Receives $20M Funding from Leonid Capital Partners to Develop Novel Programs for Pets

Shots:

• Anivive secured a $20M investment from Leonid to advance research of its programs, expand manufacturing, & support the marketing of its valley fever vaccine for canines
• Funding follows a $33M NIAID contract with NIH to develop human vaccine for the fungus Coccidioides, which causes Valley fever, leading to ~$80M in preorders & contracts
• Anivive leverages its AI platform to accelerate drug discovery & development by repurposing human treatments for veterinary oncology, antivirals, & antifungal vaccines. Additionally, its direct-to-veterinarian sales platform, Engage, has processed ~9,000 orders since its launch in early 2024

Ref: PRNewswire | Image: Pet Honesty

Related News:- Virbac Launches Zenifel Pheromone Product to Address Stress-Related Behaviors in Cats

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com